Stemokin / Neogen
What is it?
Synthetic Ile–Glu–Trp tripeptide (IEW), studied in hematopoietic experiments and Russian clinical immune research. It is distinct from whole tissue extracts.
Research context
Synthetic Ile–Glu–Trp tripeptide (IEW), studied in hematopoietic experiments and Russian clinical immune research. It is distinct from whole tissue extracts.
- Working classification
- Peptide / preparation research
- Research collection
- Peptide bioregulation · editorial grouping
- Institutional provenance
- Not established for this compound record
- Last evidence review
- Full evidence review pending; source-check scope appears with each publication below.
What do we know?
- Human research
- —Comparative clinical report; methods and overlap unresolved
- Study methods
- —Source-specific designs and limitations below
- Independent replication
- —Related reports are not automatically independent evidence
- Source access
- —Linked publications; access and review scope shown per record
- Safety evidence
- —Clinical safety, product equivalence and interactions not established by this collection
These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.
Explore the expanded peptide research collection and unresolved source trails ↗
Linked sources
Explore the research map and unresolved leads ↗
Chemical Platform for the Preparation of Synthetic Orally Active Peptidomimetics with Hemoregulating Activity.
Preparation-specific research; no equivalence inferred
Deigin V, Ksenofontova O, Khrushchev A, Yatskin O, Goryacheva A, Ivanov V. · ChemMedChem
Five cyclic analogues, numbered 3–7, were synthesized; three showed activity in experimental hematopoietic assays. Normal-marrow stimulation and post-irradiation recovery differ. Oral activity is not a pharmacokinetic measurement.
- Population / setting
- See original report; human, animal and laboratory components must be distinguished.
- What was checked
- Indexed metadata and abstract checked via Europe PMC. Original full methods not reviewed.
Limitations & review scope
- Full methods, preparation identity and risk of bias require appraisal.
- Related publications may share experiments; source count is not independent-study count.
Source checked 2026-10-02. This is a source-linked record, not a completed evidence review.
[Immunogenic peptide neogen stimulates postradiation recovery thrombopoiesis].
Preparation-specific research; no equivalence inferred
Ziablitskiĭ VM, Semina OV, Semenets TN, Starosel'skaia AN, Romanovskaia VN, Mikhal'skaia TIu, Poverennyĭ AM, Deĭgin VI. · Radiatsionnaia biologiia, radioecologiia
Neogen was investigated for platelet and bleeding-time recovery after irradiation in mice. Animal recovery endpoints do not establish clinical hematologic benefit.
- Population / setting
- See original report; human, animal and laboratory components must be distinguished.
- What was checked
- Indexed metadata and abstract checked via Europe PMC. Original full methods not reviewed.
Limitations & review scope
- Full methods, preparation identity and risk of bias require appraisal.
- Related publications may share experiments; source count is not independent-study count.
Source checked 2026-10-02. This is a source-linked record, not a completed evidence review.
Novel Peptidomimetic Cyclo-{E(I)-E(W)}Na (CP-88) with Hematopoietic Activity Sustained in Invasive and Oral Administration: Experimental and Preclinical Evaluation
Defined synthetic peptide / analogue
Vladislav Deigin, Yulia Vinogradova, Dmitriy Vinogradov, Natalia Linkova, Anastasiia Dyatlova, Dmitrii Medvedev, Alexander Krasichkov, Victoria Polyakova · International Journal of Molecular Sciences 25(24):13385
Mouse and laboratory experiments report colony-forming activity, CD34-positive-cell changes and NF-κB reporter activation. These do not establish long-term stem-cell self-renewal, direct Toll-like-receptor binding or a causal NF-κB mechanism. Oral experimental activity does not establish human pharmacokinetics; preclinical safety extrapolations are not safe human doses.
- Population / setting
- Source-specific experimental population
- What was checked
- Original full text retrieved from Europe PMC; experimental scope and interpretation checked. Supplementary methods and independent replication remain review targets.
Limitations & review scope
- Independent replication and full risk-of-bias appraisal remain unresolved.
- No personalized treatment or safety conclusion follows from this record.
Source checked 2026-10-02. This is a source-linked record, not a completed evidence review.
Advancement from Small Peptide Pharmaceuticals to Orally Active Piperazine-2,5-dion-Based Cyclopeptides
Defined synthetic peptide / analogue
Vladislav Deigin, Natalia Linkova, Olga Volpina · International Journal of Molecular Sciences 24(17):13534
Development-group review connecting small peptides with cyclic peptidomimetics, including AWE18. AWE18 and CP-88 are separate candidates. Review descriptions of oral activity are not independent clinical trials.
- Population / setting
- Source-specific experimental population
- What was checked
- Review full text retrieved via Europe PMC. Primary compound-specific studies require separate appraisal.
Limitations & review scope
- Independent replication and full risk-of-bias appraisal remain unresolved.
- No personalized treatment or safety conclusion follows from this record.
Source checked 2026-10-02. This is a source-linked record, not a completed evidence review.
Stemokin in treatment and prevention of pyoderma in military personnel
Defined synthetic peptide / analogue
V. V. Gladko, N. N. Kakhishvili, S. A. Masyukova · See linked publication
The report compares adjunctive treatment in groups of 39 and 37, and prevention in groups of 40 and 36. Reported recovery was 74.36% versus 21.62%; reported infection incidence was 17.5% versus 58.3% during follow-up up to 12 months. Allocation and blinding are unclear. The 2011 dissertation appears to report overlapping groups; neither publications nor the two investigations establish 152 unique participants.
- Population / setting
- Source-specific experimental population
- What was checked
- Russian conference abstract read. Full dissertation and participant-overlap audit remain pending.
Limitations & review scope
- Independent replication and full risk-of-bias appraisal remain unresolved.
- No personalized treatment or safety conclusion follows from this record.
Source checked 2026-10-02. This is a source-linked record, not a completed evidence review.